激光与抗血管内皮生长因子治疗早产儿视网膜病变的真实世界视觉结局
回顾性干预性病例系列,纳入在UCLA医疗中心接受早产儿视网膜病变筛查并在Stein眼科研究所和/或Doheny眼科研究所随访的175例婴儿(350只眼),比较初始抗VEGF治疗与初始激光治疗的视觉结局。与初始激光治疗相比,初始抗VEGF治疗与弱视发生率降低相关(aOR=0.6-0.86,P<.0001),而视神经萎缩、斜视和近视发生率两组无差异。
要点
- 初始抗VEGF治疗较初始激光治疗与弱视发生率降低相关(aOR=0.6-0.86,P<.0001)。
- 抗VEGF组与激光组在视神经萎缩(P=.79)、斜视(P=.98)和近视(P=.93)发生率上无差异。
- 接受激光治疗的婴儿较未治疗者更可能出现重度近视(aOR=1.02-1.3,P=.023)、弱视(aOR=1.12-1.61,P=.002)和视神经萎缩(aOR=1.01-1.32,P=.045)。
核心结论
- 这些发现增加了抗VEGF治疗相较于初始激光治疗的优势,尤其是在后部早产儿视网膜病变中。
研究设计与样本
- 回顾性、干预性病例系列,纳入在UCLA医疗中心接受早产儿视网膜病变筛查并在Stein眼科研究所和/或Doheny眼科研究所(加利福尼亚州洛杉矶)进行门诊眼科随访的患者。
- 从9年期间539例婴儿(1078只眼,32.4%随访率)的筛查人群中,共175例婴儿(350只眼)纳入分析,平均胎龄28.2周,出生体重1059克。
主要发现
- 15只眼接受初始抗血管内皮生长因子(anti-VEGF)治疗,59只眼接受初始激光治疗。
- 在控制胎龄和出生体重后,初始抗VEGF治疗相较于初始激光治疗与弱视发生率降低相关(aOR=0.6-0.86,P<.0001)。
- 抗VEGF治疗组与激光治疗组之间视神经萎缩(P=.79)、斜视(P=.98)和近视(P=.93)发生率无差异。
- 接受抗VEGF治疗的婴儿较接受激光治疗的婴儿有更多的后部病变(P=.041)。
- 接受激光治疗的婴儿较未治疗婴儿更可能出现重度近视(aOR=1.02-1.3,P=.023)、弱视(aOR=1.12-1.61,P=.002)和视神经萎缩(aOR=1.01-1.32,P=.045)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To characterize visual outcomes in children screened for retinopathy of prematurity (ROP). DESIGN: Retrospective, interventional case series. METHODS: Patients who received ROP screening examinations at UCLA Medical Centers and were followed with outpatient eye examinations at Stein Eye Institute and/or Doheny Eye Institute (Los Angeles, California) were included. Data were collected on birth characteristics, worst type of ROP, and ROP treatment. Adverse visual outcomes included myopia, strabismus, amblyopia, macular dragging, and optic atrophy. Snellen visual acuity was reported for children 4 years and older. RESULTS: A total of 175 infants (350 eyes) were included for analysis (mean gestational age = 28.2 weeks and birth weight = 1059 g) from a screening population of 539 infants (1078 eyes, 32.4% follow-up) over a 9-year period. Fifteen eyes received primary anti-vascular endothelial growth factor (anti-VEGF) therapy, whereas 59 eyes received primary laser therapy. Primary anti-VEGF therapy, as compared with primary laser treatment, was associated with a decreased incidence of amblyopia (adjusted odds ratio [aOR] = 0.6-0.86, P < .0001) after controlling for gestational age and birth weight. The rates of optic atrophy (P = .79), strabismus (P = .98), and myopia (P = .93) were not different between anti-VEGF and laser treatment groups. Infants receiving anti-VEGF therapy had more posterior disease than laser-treated infants (P = .041). Infants receiving laser therapy were more likely to have severe myopia (aOR = 1.02-1.3, P = .023), amblyopia (aOR = 1.12-1.61, P = .002), and optic atrophy (aOR = 1.01-1.32, P = .045) than infants not treated. CONCLUSION: These findings add to the advantages of anti-VEGF treatment compared with primary laser treatment, particularly in posterior ROP.
引用
- Gundlach BS, Kokhanov A, Altendahl M, et al. Real-World Visual Outcomes of Laser and Anti-VEGF Treatments for Retinopathy of Prematurity. Am J Ophthalmol. 2021. PMID: 34788594. doi:10.1016/j.ajo.2021.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。